C-ANCA Titer Test

If you have unexplained kidney problems, chronic sinus disease that will not go away, lung nodules, or blood in your urine alongside systemic symptoms like fatigue, fever, and weight loss, a C-ANCA titer can tell you whether your immune system is attacking your own blood vessels. That answer matters because the disease it detects, called ANCA-associated vasculitis (AAV), can cause permanent organ damage if it is not caught early.

C-ANCA (cytoplasmic anti-neutrophil cytoplasmic antibody) titer measures a specific pattern of autoantibodies in your blood, detected by shining fluorescent light on a slide of white blood cells. When positive, it usually means your immune system is producing antibodies against a protein called proteinase 3 (PR3), which sits inside your neutrophils, the white blood cells that normally fight infection. These antibodies can turn your neutrophils against the walls of your smallest blood vessels, causing inflammation and tissue destruction.

What C-ANCA Reflects

Your C-ANCA titer reflects a breakdown in immune tolerance, your body's built-in rule not to attack its own cells. When that tolerance fails, specialized immune cells begin producing antibodies against PR3, a protein stored in tiny compartments inside neutrophils. These anti-PR3 antibodies bind to neutrophils that have been activated by infection or inflammation, causing them to release toxic enzymes, generate damaging oxygen molecules, and form web-like structures called neutrophil extracellular traps (NETs). This cascade attacks the walls of small blood vessels in your kidneys, lungs, sinuses, skin, and nerves.

The test uses a technique called indirect immunofluorescence (IIF). A lab technician applies your serum (the liquid part of your blood) to a slide of preserved neutrophils, then looks for a characteristic granular, cytoplasmic staining pattern under a fluorescence microscope. The "titer" is the highest dilution of your serum that still shows this pattern, reported as a ratio like 1:20, 1:40, 1:80, and so on. A higher titer means more antibody is present.

Granulomatosis with Polyangiitis (GPA)

The condition most strongly linked to a positive C-ANCA is granulomatosis with polyangiitis, formerly called Wegener's granulomatosis. GPA causes inflammation in the small blood vessels of the upper airways (sinuses, nose, ears), lungs, and kidneys. It can present as chronic sinusitis that does not respond to antibiotics, lung nodules or hemorrhage, and rapidly declining kidney function. Left untreated, GPA can be fatal. A positive C-ANCA in someone with these symptoms is a powerful diagnostic signal.

In a large European standardization study of 1,282 patients, C-ANCA by IIF had a sensitivity of 64% and specificity of 95% for GPA. When combined with a confirmatory PR3 antibody test (an immunoassay, a lab method that directly measures the specific antibody rather than a staining pattern), specificity rose to 99% with 73% sensitivity for AAV overall. A meta-analysis pooling data across multiple studies found C-ANCA IIF sensitivity around 75% and specificity around 98% for AAV. These numbers mean that a positive result at high titer, in the right clinical setting, is strong evidence of vasculitis.

Other Disease Associations

C-ANCA and the closely related PR3-ANCA immunoassay (which directly measures the specific antibody rather than the staining pattern) also have diagnostic value outside of GPA. In a study of 173 patients with inflammatory bowel disease, PR3-ANCA measured by immunoassay at or above 3.5 U/mL had 44.5% sensitivity and 95.6% specificity for ulcerative colitis versus other intestinal conditions. Higher levels also predicted the need for steroid therapy, with 75% sensitivity and 69% specificity.

ANCA positivity has also been found in systemic sclerosis. In a cohort of 1,303 patients with systemic sclerosis, those who were ANCA-positive had a higher rate of interstitial lung disease and pulmonary embolism. ANCA-associated interstitial lung disease carries a high and early mortality rate, which is why some experts recommend checking ANCA in all patients with unexplained fibrotic lung disease.

Can ANCA Appear Before Symptoms?

Yes. A case-control study of 85 individuals found that ANCA antibodies can develop a median of two to three years before vasculitis symptoms appear. This means the autoimmune process is quietly building before it becomes clinically obvious, and it raises the question of whether earlier detection might allow earlier intervention. In a 10-year retrospective study of 1,024 Italian subjects, both pANCA (perinuclear ANCA) and cANCA were independent negative prognostic factors for overall survival in patients with concurrent autoimmune diseases.

Relapse Prediction and Serial Monitoring

One of the most debated questions is whether a rising C-ANCA or PR3-ANCA titer can predict a disease flare. The evidence is mixed. A meta-analysis found that ANCA rises often precede relapses within six months, but the prediction becomes much less reliable over twelve months. Expert consensus and the 2022 EULAR guidelines recommend against changing treatment based on a titer rise alone, without accompanying clinical symptoms.

That said, in a study of 110 AAV patients treated with rituximab (a B-cell-depleting therapy), patients whose PR3-ANCA remained persistently positive or reappeared after treatment had a significantly higher relapse rate than those who achieved sustained antibody negativity. In another study of 93 patients, increased PR3-ANCA levels during complete remission were associated with a higher risk of severe relapse, especially in patients with kidney involvement or lung hemorrhage.

Mortality and Long-Term Outcomes

AAV is a serious disease with real mortality risk. In a study of 484 AAV patients, the leading causes of death were cardiovascular disease, infection, cancer, and kidney failure. A meta-analysis confirmed that AAV patients have significantly increased risks of stroke, heart attack, ischemic heart disease, venous blood clots, and cardiovascular death compared to the general population. A 15-year multicenter retrospective study of 407 patients identified age, ANCA type (PR3 versus MPO), kidney biopsy findings, kidney filtration rate (GFR), and inflammatory markers including CRP (C-reactive protein, a general measure of inflammation) as long-term survival predictors.

PR3-ANCA (C-ANCA) and MPO-ANCA (P-ANCA) patients have different risk profiles. In the mortality study, MPO-ANCA patients had a higher risk of cardiovascular death, while PR3-ANCA patients tended to have higher relapse rates. This distinction between antibody types carries real clinical meaning for monitoring strategy and treatment decisions.

Reference Ranges and Interpretation

C-ANCA titer by IIF is typically reported as either negative or positive at a specific dilution (for example, 1:20, 1:40, 1:80, 1:160, or higher). Each lab sets its own positive cutoff based on the assay system used, and there is no single universal numeric threshold. Comparing results across different labs or assay platforms is unreliable because the techniques, substrates, and scoring methods vary.

A retrospective study of 288 patients found that PR3/MPO-ANCA levels at or above 65 U/mL (measured by immunoassay, a related but more quantitative test) were strongly associated with true AAV versus mimicking conditions, with an odds ratio of approximately 34 and a negative predictive value of 0.98 below this cutoff. Always compare your results within the same lab and assay method over time for the most meaningful trend.

When Results Can Be Misleading

The most common source of a misleading C-ANCA result is interference from antinuclear antibodies (ANA), which are antibodies directed against the cell nucleus. In a case series, ANA produced false-positive ANCA patterns on IIF testing, because the nuclear staining on the slide can be misread as a cytoplasmic pattern. If you have a known ANA-positive autoimmune condition (such as lupus), your C-ANCA result should always be confirmed with a specific PR3 or MPO immunoassay.

C-ANCA can also be positive without vasculitis in infections like tuberculosis (found in about 44% of TB patients in one study), inflammatory bowel disease, and IgG4-related disease. This is why guidelines stress that a positive C-ANCA should never be interpreted in isolation. The clinical picture, organ involvement, and confirmatory PR3/MPO testing all matter.

Drug-Induced ANCA Positivity

Certain medications can trigger ANCA production and, in some cases, actual vasculitis. The most well-documented culprits are antithyroid drugs (propylthiouracil, thiamazole, carbimazole). A multicenter study of 45 patients with antithyroid drug-induced ANCA vasculitis found that these cases are generally less severe and have lower relapse rates than primary AAV, and most improve when the drug is stopped. Hydralazine (a blood pressure medication), levamisole-adulterated cocaine, and minocycline (an antibiotic) have also been reported to induce ANCA positivity. If you are taking any of these and test positive, your doctor should consider drug-induced ANCA before concluding you have primary vasculitis.

Tracking Your Trend

A single C-ANCA titer tells you whether the antibody is present and roughly how much of it there is. But because ANCA levels fluctuate, and because a rising titer does not automatically mean a flare is coming, serial measurement is more valuable than any single reading. If you have been diagnosed with AAV, tracking your titer over time alongside clinical symptoms gives your care team a richer picture of your disease trajectory.

For monitoring known AAV, most specialists check ANCA titers every three to six months, or more frequently if symptoms change. If you are in remission and your titer stays negative, that is reassuring, especially after rituximab therapy where sustained negativity is linked to lower relapse risk. If your titer rises, that alone is not cause for alarm, but it should prompt closer clinical monitoring. The key is: track the trend, not the single number.

What to Do with Your Result

If your C-ANCA titer comes back positive and you have symptoms like bloody urine, persistent sinus disease, lung nodules, unexplained weight loss, or numbness in your extremities, the next step is a confirmatory PR3-ANCA (or MPO-ANCA) immunoassay, kidney function testing (creatinine, eGFR, urinalysis with microscopy), inflammatory markers (CRP, ESR), and a referral to a rheumatologist or nephrologist with experience in vasculitis. Many patients will also need a tissue biopsy (kidney, lung, or sinus) to confirm the diagnosis and guide treatment intensity.

If your C-ANCA is positive but you have no symptoms, do not panic, but do not ignore it either. Repeat the test in four to six weeks, add a PR3/MPO immunoassay for confirmation, and make sure your kidney function and urinalysis are checked. Remember that ANCA antibodies can appear years before symptoms develop. A confirmed positive with normal organ function warrants periodic monitoring rather than immediate treatment.

If your C-ANCA is negative but your clinical suspicion is high (for example, rapidly worsening kidney function with blood in the urine), the test may have missed the diagnosis. C-ANCA IIF misses about 25% to 36% of AAV cases. A negative result does not rule out vasculitis, and further workup including PR3/MPO immunoassay, biopsy, and specialist evaluation should still proceed.